





Research for Impact

To: Ministry of Health FAO: Health Cabinet Secretary Mutahi Kagwe Afya House Cathedral Road Nairobi, Kenya

Email: ps@health.go.ke

August 31, 2021

Dear Sen. Kagwe,

The Evidence-Based Medicine Consultancy Ltd (E-BMC Ltd) is a UK-based independent medical research company that contributes to the quality of healthcare globally through the rigorous evaluation of medical evidence to support clinical practice guidelines. The Frontline Covid Critical Care Alliance (FLCCC) Alliance is a U.S based non-profit humanitarian organization made up of renowned, world-expert clinician-researchers whose sole mission over the past year has been to develop and disseminate the most effective treatment protocols for covid-19.

We commend the efforts of the Republic of Kenya in managing to limit the spread of Covid-19 and we understand that the government is anxious to keep cases at a minimum. Widespread availability of safe and effective vaccines for those who choose to get vaccinated has been challenging for most countries. In addition, current covid vaccines, which can help protect against severe disease, may not be as effective against certain variants. It is our view that continuing success in controlling the pandemic must involve treating at the earliest signs of symptoms and/or a positive test result, which will help prevent deterioration and need for hospitalisation.

Over the past four months, E-BMC Ltd has been working together with the FLCCC to encourage governments around the world to adopt re-purposed existing drugs for the early treatment of covid-19. One such drug is ivermectin, a safe medicine which has been used for nearly 40 years to treat parasitic infections. New evidence show that it has potent antiviral and anti-inflammatory properties as well.

E-BMC Ltd presented the evidence on ivermectin to prevent and treat covid-19 to the British Ivermectin Recommendation Development (BiRD) panel in February 2021. The BiRD group includes researchers and doctors from around the world who have been seeking effective treatments to combat the pandemic. The BiRD panel deliberated on the evidence for the use of ivermectin against covid-19, including evidence and considerations on cost, safety, acceptability, feasibility, equity and people's values and preferences. The meeting resulted in a recommendation in favour of ivermectin as a covid-19 frontline therapy.

FLCCC





Both BiRD and FLCCC recommend ivermectin be used for treatment of covid-19 in early out-patient disease. We recommend that ivermectin be used at a dose of 0.4 mg/kg – 0.6 mg/kg, along with a number of adjunct therapeutics, which are detailed in the regularly updated

I-MASK+ Prevention & Early Treatment Protocol¹. We strongly recommend that ivermectin be continued for 5 days or until recovered. For hospitalized covid patients, please refer to the MATH+ Protocol².

We also recommend that ivermectin be used as covid-19 prophylaxis on a large scale through mass distribution of ivermectin in the dose of 0.2mg/kg (12mg for a 60 kg person) twice-weekly to adults to decrease transmission amongst the general population in the current crisis. We believe this will save thousands of lives and reduce the suffering of millions.

Ivermectin's ability to beat covid-19 can be evidenced in many parts of the world, including the Dominican Republic, India, Zimbabwe and South Africa, as well as in other African countries where mass administration of ivermectin against parasitic infections is practiced. More than 3.7 billion people have been treated with ivermectin for parasitic infections and it has been found to be extremely safe.

On behalf of our our members and our numerous affiliated organisations who have been providing ethical medical guidance during this health emergency, we hope our message will be given the necessary attention for the better health of Kenyans and the Kenyan economy.

Should you need any further information, please do not hesitate to contact us via: <u>newsletter@bird-group.org</u>.

Yours Sincerely,

Dr. Tess Lawrie on behalf of the BiRD Group, and Dr Pierre Kory on behalf of the FLCCC, and affiliated organisations:

305 Northgate House, Upper Borough Walls, Bath BA1 1RG, United Kingdom. +44 7826 939 464 – <u>tess@e-bmc.co.uk</u> – www.e-bmc.co.uk Registered in England and Wales no. 08690151

¹ <u>https://covid19criticalcare.com/covid-19-protocols/i-mask-plus-protocol/</u>

² <u>https://covid19criticalcare.com/wp-content/uploads/2021/01/FLCCC-Alliance-MATHplus-Protocol-ENGLISH.pdf</u>



































Doctors for Covid Ethics

CANADIAN COVID CARE ALLIANCE Alliance canadienne pour la prévention et prise-en-charge de la covid















Philippine Society for Orthomolecular Medicine











TRANSFORMATIVE HEALTH JUSTICE (NPC)